CVS Caremark becomes second major PBM to settle FTC insulin rebating case

By ··2 min read

The FTC reached a proposed consent order with CVS Health's Caremark Rx and its group purchasing organisation Zinc Health Services, resolving allegations that rebate practices inflated insulin list prices. The FTC says the terms will deliver $8.5 billion in consumer savings over a decade, plus up to $4.5 billion through point-of-sale rebates.

The Federal Trade Commission announced on July 14, 2026 a settlement with Caremark Rx LLC and Zinc Health Services LLC, the pharmacy benefit manager and group purchasing organisation owned by CVS Health. The proposed consent order resolves the agency's insulin rebating case against Caremark, making it the second of the three largest PBMs to settle after Express Scripts did so in February. The FTC said the terms would deliver $8.5 billion in consumer savings over the next decade, with up to $4.5 billion more through point-of-sale rebates over the same period.

The FTC filed its administrative complaint in September 2024 against Caremark, Express Scripts and OptumRx under Section 5 of the FTC Act. It alleged that the PBMs built a rebate-centred system that pushed insulin manufacturers to compete for preferred formulary placement on the size of rebates off list price rather than on net price. Under the proposed order, Caremark must stop discriminating against low wholesale acquisition cost versions of a drug on its standard formularies and may not interfere with hub pharmacies. Although the complaint focused on insulin, the structural terms apply to all prescription drugs.

CVS contested the case, and the PBMs jointly countersued the agency. In March 2026, when the FTC disclosed significant progress in settlement talks, a CVS spokesperson said the company was negotiating in good faith to avoid prolonged litigation. The FTC withdrew the Caremark matter from adjudication that month to allow negotiations to continue.

In August 2025 Chief Judge Mitchell Goldberg of the Eastern District of Pennsylvania ordered Caremark entities to pay $289.9 million under the False Claims Act in a case brought by former Aetna actuary Sarah Behnke, after finding that Caremark caused false drug cost reports to be submitted to Medicare Part D. The judgment trebled $95 million in damages and added $4.87 million in civil penalties, and Caremark has appealed to the Third Circuit. Separately, CVS Pharmacy is among the defendants in the insulin pricing lawsuit filed by the Texas Attorney General in October 2024.

The proposed consent agreement was opened to a 30-day public comment period. OptumRx is now the only one of the three PBMs yet to settle, and its case has been withdrawn from adjudication while the parties consider a proposed consent agreement.

Cite this report

The Precedent. "CVS Caremark becomes second major PBM to settle FTC insulin rebating case." August 27, 2026. https://theprecedent.org/article/cvs-caremark-becomes-second-major-pbm-to-settle-ftc-insulin-rebating-case

Companies in this report